Alprazolam

Introduction Overview

Generic Name

alprazolam

Brand Name

Xanax, Xanax XR, Niravam

Dosage Form

oral concentrate (1 mg/mL), oral tablet (0.25 mg, 0.5 mg, 1 mg, 2 mg), oral tablet, extended release (0.5 mg, 1 mg, 2 mg, 3 mg), oral tablet disintegrating (0.25 mg, 0.5 mg, 1 mg, 2 mg)

Drug Class

Benzodiazepines

Pharmacokinetics

Absorption

Alprazolam is well absorbed following oral administration, with peak plasma concentrations generally reached within 1 to 2 hours for immediate-release formulations. Extended-release tablets result in peak plasma levels at approximately 6 hours post-dose, allowing for once-daily dosing. The drug's bioavailability is high and not significantly affected by food intake, though high-fat meals may delay the time to peak concentration. Clinical studies indicate rapid onset of action correlates with prompt absorption, essential for treating acute anxiety and panic symptoms.

Distribution

Alprazolam is highly lipophilic and widely distributed throughout body tissues, including the central nervous system (CNS), where it exerts its pharmacological effects. It exhibits approximately 80% plasma protein binding, primarily to albumin. The volume of distribution is estimated around 0.8 to 1 L/kg. The ability of alprazolam to cross the blood-brain barrier rapidly contributes to its effectiveness in anxiety relief. Distribution can be influenced by patient factors like age, body fat content, and hepatic function, potentially altering drug levels.

Metabolism

Metabolized primarily in the liver via the cytochrome P450 3A4 (CYP3A4) enzyme system, alprazolam undergoes extensive hepatic metabolism producing pharmacologically inactive metabolites such as alpha-hydroxyalprazolam and beta-hydroxyalprazolam. The metabolism rate may be affected by CYP3A4 inhibitors (e.g., ketoconazole, itraconazole), which can increase alprazolam plasma concentrations and toxicity risk. Patients with hepatic impairment show reduced clearance and increased half-life, necessitating dose adjustments.

Elimination

The elimination half-life of alprazolam typically ranges from 11 to 16 hours in healthy adults but can be prolonged in elderly or debilitated patients and those with hepatic impairment. Approximately 80% of an administered dose is excreted in the urine primarily as metabolites; less than 1% is excreted unchanged. Renal impairment minimally affects elimination due to predominant hepatic metabolism. The clearance rate varies with age, liver function, and concurrent medications and influences dosing frequency and withdrawal protocols.

Dosage Forms

Adults

Available dosage forms include oral tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg), orally disintegrating tablets (0.25 mg, 0.5 mg, 1 mg, 2 mg), extended-release tablets (0.5 mg, 1 mg, 2 mg, 3 mg), and oral concentrate (1 mg/mL). The usual adult dosing for anxiety involves immediate-release tablets or ODTs at 0.25 to 0.5 mg orally three times daily, titrated up to a maximum of 4 mg/day. For panic disorder, initial immediate-release dosing is 0.5 mg three times daily with a maximum up to 10 mg/day, while extended-release tablets start at 0.5 to 1 mg once daily with a maintenance dose between 3 to 6 mg per day. Dosage increments for extended-release formulations are limited to 1 mg per day every 3 to 4 days, emphasizing gradual titration.

Adolescents

Alprazolam is not approved for use in individuals younger than 18 years old. Clinical safety and efficacy have not been established for pediatric patients, and use in this population is generally discouraged due to potential adverse effects and lack of standard dosing guidelines.

Special Populations

For elderly or debilitated patients, the recommended starting dose for anxiety is lower, at 0.25 mg orally two or three times daily with cautious titration. For panic disorder, elderly patients start at 0.25 mg two to three times daily (immediate-release/ODT) or 0.5 mg once daily (extended-release). Dose reductions are advised in hepatic impairment to avoid accumulation and toxicity. Renal impairment generally requires no dosage adjustment, but careful clinical monitoring is advised. Pregnancy is contraindicated due to teratogenic risk and neonatal withdrawal syndrome. Breastfeeding is not recommended. Dose tapering should be slow and individualized to minimize withdrawal risk.

Mechanism Of Action

Alprazolam is a short-acting benzodiazepine that exerts its anxiolytic, sedative, muscle relaxant, and anticonvulsant effects primarily through modulating the gamma-aminobutyric acid (GABA) neurotransmitter system in the central nervous system. Specifically, alprazolam binds with high affinity to the benzodiazepine site on the GABAA receptor complex, which is a ligand-gated chloride ion channel. This binding increases the frequency of chloride channel opening events induced by GABA, enhancing neuronal inhibition and hyperpolarizing neurons. The enhanced chloride influx leads to a generalized decrease in neuronal excitability.

Pharmacological Actions

Enhancement of GABAergic neurotransmission producing anxiolytic effects
Sedation and anxiolysis through central nervous system depression
Muscle relaxant properties via spinal cord and supraspinal mechanisms
Anticonvulsant activity by stabilizing neuronal membranes and decreasing synaptic transmission
Reduction of excessive neuronal discharge implicated in anxiety and panic disorders
Anxiolytic and CNS depressant effects facilitating acute relief of anxiety and panic symptoms
Potential amnesic effects due to hippocampal GABAA receptor activation
CNS depressant effects contributing to sedation and hypnosis

Therapeutic Clinical Uses

Treatment of generalized anxiety disorder (GAD)
Management of panic disorder with or without agoraphobia
Short-term relief of anxiety symptoms associated with depression
Off-label use for situational anxiety or acute stress reactions
Adjunct use in some cases of insomnia related to anxiety
Management of anxiety symptoms during depressive episodes

Side Or Adverse Effects

Drowsiness and sedation
Dizziness and light-headedness
Fatigue and muscle weakness
Impaired coordination and balance, increasing fall risk particularly in elderly
Memory impairment and difficulty concentrating
Paradoxical reactions including increased anxiety, agitation, or aggression
Respiratory depression especially when combined with other CNS depressants
Dependence, tolerance, and potential for abuse
Withdrawal symptoms upon abrupt discontinuation such as seizures and tremors
Gastrointestinal disturbances like nausea or dry mouth
Blurred vision and diplopia
Headache
Confusion and disorientation especially in elderly or debilitated patients
Potential for jaundice or hepatic dysfunction (rare)

Precautions

Use with caution in patients with respiratory conditions such as COPD or sleep apnea
Assess risk of substance abuse or dependence prior to initiating therapy
Careful dose titration and frequent reassessment in elderly or debilitated individuals
Avoid abrupt discontinuation to decrease risk of withdrawal symptoms
Monitor for signs of depression and suicidal ideation during treatment
Avoid concomitant use with CYP3A4 inhibitors to prevent toxicity
Adjust dose in hepatic impairment due to reduced metabolism
Avoid use during pregnancy and breastfeeding due to risk of fetal harm and neonatal withdrawal
Monitor for cognitive and motor impairment, especially in activities requiring alertness
Educate patients about avoiding alcohol and other CNS depressants

Warnings

High potential for abuse, dependence, and addiction
Risk of life-threatening respiratory depression when combined with opioids or alcohol
Potential for severe withdrawal symptoms including seizures and psychosis
Contraindicated in narrow-angle glaucoma
Not to be used concomitantly with strong CYP3A4 inhibitors such as ketoconazole or itraconazole
Use during pregnancy can cause fetal harm, including birth defects and neonatal withdrawal syndrome
May impair mental and physical abilities required for hazardous tasks like driving
Dosage reduction should be gradual to prevent withdrawal syndrome
Potential for paradoxical reactions such as increased agitation and aggressive behavior
Use with caution in patients with a history of depression or suicidal thoughts

Contraindications

Hypersensitivity to alprazolam or other benzodiazepines
Concurrent use of itraconazole or ketoconazole due to risk of increased plasma alprazolam levels
Narrow-angle glaucoma
Pregnancy due to teratogenicity and neonatal withdrawal risk
Severe respiratory insufficiency or sleep apnea (relative contraindication)
Myasthenia gravis (relative contraindication)

Drug Interactions

Concomitant use with opioids or other CNS depressants markedly increases risk of sedation, respiratory depression, and death
CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) increase alprazolam plasma levels and toxicity risk
CYP3A4 inducers (e.g., rifampin, carbamazepine) decrease alprazolam efficacy by lowering plasma levels
Other benzodiazepines or sedative hypnotics may have additive CNS depressant effects
Alcohol consumption potentiates CNS depression and respiratory compromise
Certain antidepressants may potentiate sedative effects
Muscle relaxants and antiepileptics can interact to enhance sedation and motor impairment
Interaction with cimetidine may increase alprazolam levels
Concomitant use with valproate may affect plasma concentrations

Preparations Of The Drug

Oral concentrate 1 mg/mL solution
Immediate-release oral tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg
Orally disintegrating tablets (ODT): 0.25 mg, 0.5 mg, 1 mg, 2 mg
Extended-release tablets: 0.5 mg, 1 mg, 2 mg, 3 mg
Commercially available under brand names such as Xanax, Xanax XR, Niravam